Bone marrow cell study with a special carbon label
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study uses a special label (carbon 13) to track bone marrow cells in people with a pre-cancer condition called MGUS. It aims to learn how these cells work, which may help understand the condition better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years old or older
- Able to give permission to take part in the study
- Diagnosed with a type of MGUS (a condition with abnormal proteins in the blood)
- Not currently on medicines that weaken the immune system
- No past bad reactions to medicine used for sedation during procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
This study compares the gut bacteria of healthy adults (age 45+) with those who have a blood condition called monoclonal gammopathy. The goal is to see if gut bacteria patterns differ between the two groups.
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
This trial uses special imaging scans to detect amyloidosis (abnormal protein buildup) early in people who have monoclonal gammopathy (an abnormal blood protein). The goal is to find amyloidosis before it causes serious organ damage.
This study screens adults aged 40 and older for early signs of MGUS (a benign blood condition) and multiple myeloma (a blood cancer). You'll fill out questionnaires about your health to help with early detection.
Hear when a new Monoclonal Gammopathy of Undetermined Significance (MGUS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.